Powered by
CANTON TWP.—Officials at MMS Holdings, the Canton Township-based contract pharmaceutical research firm, announced that the company’s MMS Academy has launched new courses in inspection readiness and clinical programming for clinical …
CANTON TWP.–MMS Holdings, a contract research organization for the pharmaceutical industry, has joined the Decentralized Trials and Research Alliance, an organization launched in December to unite healthcare companies, regulators, patient …
CANTON TWP.—The life sciences regulatory and clinical data consultant MMS Holdings announced it had been retained by Thunder Bay, Ontario-based IGY Life Sciences to further the development of IgY-110, an …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), developers of novel treatments to reduce cholesterol in the bloodstream, announced the United States commercial availability of Nexlizet tablets. Nexlizet is a combination of …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …
CANTON TWP.–MMS Holdings Inc., the contract research organization for the pharmaceutical industry based in Canton Township, announced that its regional operations in South Africa more than doubled in the past …
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging to consumers for the pharmaceutical industry, reported net income of $406,617 or 3 cents a share, up 45 percent in …